Centauri Therapeutics has closed a £24 Million Series A investment round to support the advancement of its antimicrobial resistance R&D work, using its Alphamer platform.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,